WP 1-Tuberculosis

The Malaria Work Package is made of two sub-work packages, one dealing with the diagnosis and management of childhood TB and the other with TB drug-resistance; these activities will be coordinated by MRCG.


  1. Strengthen diagnostics competency for Adult and childhood TB within clinical setting in the Network
  2. Strengthen laboratory diagnostics of TB using novel diagnostics techniques such as GeneXpert
  3. Strengthen capacity of investigators at sites to write competitive winning grant applications
  4. Set up platform of sites for drug susceptibility testing (DST) to first and second line drugs in west Africa


  • TB   Activity 1Improve the recognition of childhood TB   within the national health services through a specific integrated training program for appropriate referrals for diagnosis.
  • TB   Activity 2: To facilitate the roll out of novel diagnostics for children and   adults
  • TB–Activity   3: To train participants in the principles of robust study design and   sampling for drug-resistance surveys and clinical trials of new treatments,   diagnostics and prospective markers
  • TB-Activity   4: To build practical skills   for drug-susceptibility testing (DST) to first and second-line drugs


WP 2-Malaria

The Malaria Work Package aims at increasing capacities for the evaluation of new interventions/treatments/vaccines able to further reduce malaria transmission when this is already low, and possibly interrupt it. It is divided in four sub-objectives, each of them translating in several activities.


  • To build capacities for the evaluation of new community-based interventions aimed at interrupting malaria transmission in West Africa
  • To build capacities for the evaluation of the efficacy of new insecticides and the monitoring of insecticide resistance
  • To build capacities to determine safety and efficacy of new treatments/vaccines
  • To set up a controlled human malaria infection (CHMI) model in The Gambia, with the aim of conducting early phase trials on new treatments/vaccines. The Gambia has functioning insectaries, culture facilities and excellent clinical facilities where volunteers will be carefully monitored. The CHMI will be “exported” to Senegal pending availability of resources. 


To build capacities for the evaluation of new community-based interventions aimed at interrupting malaria transmission in West Africa

  • Activity 1: Training in the diagnosis of malaria infections with molecular techniques
  • Activity 2: Training in implementation of community-based cluster randomized trials
  • Activity 3: Training on Malaria-specific trial design and grant writing

To build capacities for the evaluation of the efficacy of new insecticides and the monitoring of insecticide resistance

  • Activity 4: Training on entomological characteristics and profile
  • Activity5: Training on insecticide resistance profile

To setting up a controlled human malaria infection (CHMI) model

  • Activity 6: Setting up the model
  • Activity 7: Exporting the model to other institutions


WP 3 – HIV

THIV remains a public health menace in West Africa despite its relatively low prevalence compared to in East and Southern Africa [12]. According to the UNAIDS Global epidemic update and health sector progress towards universal access report 2011, none of the West African countries was among those who achieved 80% coverage of HIV treatment; only Benin was cited amongst those with 60% coverage and no West African country had a decline of more than 39% of number of children with new infections between 2009-2011. In Guinea Bissau the number of new infections among children increased. Nigeria was listed amongst the countries with less than 25% PMTC coverage despite being just behind South Africa in HIV burden globally. Furthermore, no PrEP trial and limited implementation of PrEP and TASP has been carried out in at-risk populations such as MSM, sero-discordants, or sex-workers cohorts in the region. To improve the situation, WANETAM- will carry out the following work package activities that will strengthen capacities in HIV surveillance for drug adherence and resistance; diagnosis and feasible viral load monitoring, including early paediatric diagnosis.


  • Establish a unified cohort database of at-risk populations and facilitate the sharing of data including ART-acquired and ART transmitted resistance  across participating sites
  • Validate and roll out Viral load assays for both HIV 1 and HIV 2
  • Facilitate a platform and train sites on HIV drug resistance testing
  • Strengthen South-South and North-South Collaboration Complete?


  • To develop the West African unified HIV cohort database
    • HIV-WP – Activity 1 – Enriching unified cohort database of at-risk populations and sharing data resource
    • HIV-WP- Activity 2 – Develop and sharing data on   ART-acquired and ART-transmitted resistance in the treatment programs.

Validate and roll out Viral load (VL) assays for HIV-1 and HIV-2

  • HIV-WP–Activity 3 – Validation of the In-house HIV-1/HIV-2 RT-PCR VL assay and Viral load POCs evaluation
  • HIV-WP-Activity 4– Phasedimplementation of VL assays

HIV specific training on drug resistance tests and VL/paediatric HIV diagnosis

  • HIV-WP-Activity 5 Training attachment for drug resistance test
  • HIV-WP-Activity 6 – Training workshop on VL and early infant diagnosis (EID)



For the first time our regional network plans to incorporate capacity building for clinical surveillance, diagnosis and preventive management for specifically soil-transmitted helminths and schistosomiasis, and for emerging Ebola threat.  Many West African countries have recently initiated mass drug anthelmintic treatment (MDA) in school children but have not set up any surveillance system. The experience of the recently emerged Ebola epidemic in the region calls for the strengthening of capacities in clinical response preparedness and laboratory diagnostic systems.  Work packages for NTD will be led by the Department de Biologie et Parasitologie, UCAD, Senegal.


  • To train and roll out molecular diagnostic tools for helminths infection
  • Molecular epidemiological survey of helminths prevalence and anthelmint
  • Capacity for clinical, laboratory and public health rapid response. 



  • NTD-WP4.1-Activity-1 Training workshop on RT-PCR for helminths and MALDI-TOF tool for Schistosomiasis Hybrid detection
  • NTD-WP-4.1 -Activity -2 – Epidemiological surveillance and building database of helminth prevalence tic resistance.
  • NTD-WP4.1 -Activity 3: Monitoring and evaluation of the development of anthelmintic resistance


  • Laboratory diagnostic training
  • Building capacity for Clinical preparedness for Ebola outbreak and control


WP 5 -Cross-Cutting Trainings

WANETAM- proposes a generic training work package that will be tailored to the needs of partner institutions to increase leadership and competency in clinical research and research support.  These opportunities will be advertised within the network.  Each Training Plan will set minimum requirements via a Training Selection Committee, who will arrange the interviews of applicants and selection of candidates.


  • Building necessary scientific capacity of scientist
  • Provide an opportunity for tailored training to the needs of partners in specific areas.
  • Deliver training and infrastructure support to financial, grants and quality management systems.
  • Provide technical support through master’s degree courses will be issued in areas of need and more so clinical trial monitoring, biostatistics and data management.


  • C-C Training -1: Post-doctoral and Senior Clinical skills training and mentorship
  • Activity 1 – Post Doctoral Mentorship
  • C-C Training-2: MSc Online courses
  • Master’s Degree Training

C-C Training-3: Professional development Courses

Clinical trial quality assurance and clinical trial monitoring;

  • epidemiological evaluation of vaccines;
  • project management and biological safety handling.
  • Project/Program Management courses
  • IATA online run course for biological sample handling and shipment
  • Epidemiological evaluation of vaccines: efficacy, safety and policy
  • Practical field-based experience

C-C Training -4: Professional development internship

  • Financial and Grant Management Internships

C-C Training 5: Laboratory Quality Assurance Training

  • Quality management to SLIMTA/SLIPTA Accreditation